Clinical Trials in Washington, 2026

Trials with a site in Washington

Status

Study

Lead sponsor

Phase

Enrol

US states

Start

Not yet open

A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)

NCT07848295Clear Cell Renal Cell Carcinoma (ccRCC)

DrugsCabozantinib·Opdivo·Nivolumab

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 1

112

Connecticut, New Jersey, New York, Ohio, Texas, Washington

2026-12-31

Recruiting

Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)

NCT07775287Colorectal Cancer

DrugsPetosemtamab·Fluorouracil·Leucovorin·Cetuximab

Genmab

Phase 3

600

California, Georgia, Washington

2026-10-15

Not yet open

Validation of cueStim for Reduction of Freezing of Gait in Parkinson's Disease

NCT07675408Parkinson's Disease With Freezing of Gait

Fortis Medical Devices Limited

Not applicable

Florida, Georgia, Kansas, Oregon, Washington

2026-10

Recruiting

Endo-SPONGE for Treatment of Anastomotic or Hartmann's Stump Leakages in Lower Pelvic Area

NCT07035431Anastomotic Leaks, Hartmanns Stump Leakage

Boston Scientific Corporation

Not applicable

California, Florida, Massachusetts, New York, Ohio, Pennsylvania, Washington, West Virginia

2026-10

Recruiting

A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT07029945Geographic Atrophy

Biojiva LLC

Phase 1/2

152

Arizona, Mississippi, Nevada, Ohio, Texas, Utah, Washington

2026-09-29

Recruiting

A Study to Test the Repeatability and Reproducibility in Rod Intercept Time Within the AdaptDx Pro in Healthy Subjects With Normal Vision (FlashForward)

NCT07860905No Disease

AdaptDx, Inc.

Observational

Washington

2026-09-18

Recruiting

A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma

NCT07815665Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC)

DrugsEnfortumab Vedotin·Pembrolizumab

Summit Therapeutics

Phase 2/3

800

Arizona, California, District of Columbia, Florida, Minnesota, Tennessee, Washington

2026-09-10

Recruiting

EMBRACE-OBS: Single-Site Observational Registry of Patient-Reported Outcomes Following MMA Embolization for Migraine

NCT07652034Migraine Disorders, Chronic Migraine Headache, Migraine

Cortex Neurovascular

Observational

Washington

2026-09-01

Recruiting

Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

NCT07722741HCC

DrugsGNOS-PV02·INO-9012

Geneos Therapeutics

Phase 2

Georgia, Louisiana, Maryland, Michigan, New York, Texas, Washington

2026-09

Not yet open

Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)

NCT07603557Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia

DrugsZola-cel·Fludarabine Phosphate·Cyclophosphamide

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 2

Massachusetts, Texas, Washington

2026-08-31

Recruiting

A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism

NCT07699471Hypoparathyroidism

MBX Biosciences

Phase 3

160

Florida, Louisiana, Nevada, New York, North Carolina, South Carolina, Texas, Washington

2026-08-26

Not yet open

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

NCT07735637Newly Diagnosed Multiple Myeloma (NDMM)

DrugsASCT·AZD0120·Melphalan·Lenalidomide

AstraZeneca

Phase 3

750

Florida, Georgia, Illinois, Michigan, Minnesota, Ohio, Texas, Washington

2026-08-25

Recruiting

Mobile Technology to Reduce Teen Substance Misuse

NCT05897164Substance Use, Substance Abuse, Suicide, Adolescent

Evidence-Based Practice Institute, Seattle, WA

Not applicable

600

Maryland, Washington

2026-08-18

Recruiting

MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma

NCT07541404Subdural Hematoma

Arsenal Medical, Inc.

Not applicable

360

Connecticut, Washington

2026-08-13

Recruiting

Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)

NCT07702032Left-sided Colorectal Cancer

DrugsPetosemtamab·MFOLFOX6·Folfiri·Cetuximab

Genmab

Phase 3

960

Arkansas, California, Georgia, Indiana, Missouri, Washington

2026-08-11

Recruiting

Within-Subject Comparison of Adipose Tissue Viability Following Liposuction

NCT07820397Liposuction

Apyx Medical

Not applicable

Ohio, Washington

2026-08-06

Recruiting

A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder

NCT07767903Generalized Anxiety Disorder

DrugUlotaront

Otsuka Pharmaceutical Development & Commercialization, Inc.

Phase 3

384

California, Florida, New Jersey, New York, Washington

2026-08-06

Recruiting

Determine the Prevalence of Exocrine Pancreatic Insufficiency (EPI) in Pediatric and Adult Participants With Alagille Syndrome After Liver Transplantation

NCT07335523Exocrine Pancreatic Insuficiency

Digestive Care, Inc.

Observational

Colorado, New York, Ohio, Oregon, Tennessee, Texas, Washington

2026-08-03

Not yet open

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes

NCT07712562Bone Marrow Failure Syndromes, Aplastic Anemias, Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Relapse

DrugDibotatug

Dren Bio

Phase 1/2

California, Florida, Georgia, New York, Ohio, Texas, Virginia, Washington

2026-08

Recruiting

Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).

NCT07680439Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor

BrainChild Bio, Inc

Phase 2

California, Georgia, Illinois, Ohio, Pennsylvania, Washington

2026-08

Recruiting

Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease

NCT07348640Steno-occlusive Disease

DrugsGadopiclenol·Gadoterate meglumine

Guerbet

Phase 3

315

California, Colorado, Illinois, Minnesota, Texas, Washington

2026-07-28

Recruiting

A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression

NCT07716098Depressive Disorder, Treatment-Resistant

DrugEsketamine

Janssen Research & Development, LLC

Phase 3

348

California, Georgia, Illinois, New York, Washington

2026-07-23

Recruiting

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

NCT06987539Generalized Myasthenia Gravis

DrugInebilizumab

Amgen

Phase 2

Pennsylvania, Texas, Washington

2026-07-21

Recruiting

A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)

NCT07601074Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection

DrugLopinavir / Ritonavir

Daré Bioscience, Inc.

Phase 2

118

Arizona, Arkansas, Utah, Washington

2026-07-17

Recruiting

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

NCT07609940Relapsed/Refractory Multiple Myeloma (RRMM)

DrugsLinvoseltamab·Tocilizumab

Regeneron Pharmaceuticals

Phase 4

California, Florida, Louisiana, Maryland, Washington

2026-07-15

Recruiting

A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome

NCT07503444Rett Syndrome

DrugFintepla

UCB BIOSCIENCES, Inc.

Phase 3

200

Arkansas, Florida, Georgia, Pennsylvania, Texas, Washington

2026-07-14

Recruiting

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

NCT07682961HIV Infections

DrugsTeropavimab·Zinlirvimab·Rilpivirine·Cabotegravir

Gilead Sciences

Phase 3

590

California, Florida, Georgia, Michigan, Missouri, Texas, Virginia, Washington

2026-07-14

Recruiting

Comparative Self-collection for Cervical Cancer Screening Pivotal Study

NCT07758140HPV, HPV - Anogenital Human Papilloma Virus Infection

Mel Mont Medical

Not applicable

260

Arizona, California, Florida, Idaho, Montana, North Carolina, Texas, Washington

2026-07-09

Recruiting

Use of Force Feedback Instruments With the da Vinci Surgical System, Model IS5000 for Mitral Valve Repair

NCT07655505Mitral Regurgitation (MR)

Intuitive Surgical

Not applicable

Georgia, New York, Washington

2026-07-06

Recruiting

Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

NCT07005180Parkinson Disease

Hillhurst Biopharmaceuticals, Inc.

Phase 2

California, Florida, Massachusetts, Michigan, New York, Washington

2026-06-30

Recruiting

A Study of ARC-02 in B-cell NHL

NCT07691606B-cell Non Hodgkin Lymphoma

DrugRituximab

Taiho Oncology, Inc.

Phase 1

140

California, Kentucky, New York, North Carolina, Virginia, Washington, Wisconsin

2026-06-22

Recruiting

Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients

NCT06513949Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

DrugAtibuclimab

Implicit Bioscience

Phase 2

Washington

2026-06-17

Recruiting

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

NCT07564401Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Novartis Pharmaceuticals

Phase 1/2

Kentucky, Texas, Washington

2026-06-16

By invitation

Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

NCT07652294Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative

DrugsSPY001·SPY002·SPY003

Spyre Therapeutics, Inc.

Phase 2

645

California, Florida, Louisiana, Rhode Island, Texas, Washington

2026-06-08

Active, closed

Kosmos Guidance Performance Evaluation Data Annotation

NCT07771270Heart, Ultrasound, Cardiac Ultrasound, Cardiac Disease

EchoNous Inc.

Observational

Washington

2026-06-05

Recruiting

A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults

NCT07628049Respiratory Syncytial Virus Infections+Metapneumovirus

GlaxoSmithKline

Phase 1/2

1,456

Georgia, Kansas, Washington

2026-06-05

Recruiting

A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

NCT07477587Multiple Myeloma (MM)

Shanghai Henlius Biotech

Phase 1

258

Arkansas, Florida, Indiana, Louisiana, Texas, Washington

2026-05-25

Recruiting

ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome

NCT07531745Dravet Syndrome

Ionis Pharmaceuticals, Inc.

Phase 1/2

Michigan, Minnesota, North Carolina, Tennessee, Washington

2026-05-21

Recruiting

A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

NCT07124078Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 2

California, District of Columbia, Florida, Georgia, New York, North Carolina, Pennsylvania, Washington

2026-05-20

Recruiting

IS-001 Injection in Patients Undergoing Robotic-Assisted Colorectal Surgery

NCT07346066Ureter Injury

Intuitive Surgical

Phase 3

146

California, Connecticut, Florida, Nevada, Ohio, Texas, Washington

2026-05-14

Recruiting

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

NCT07582432Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

DrugGamunex-C

Grifols Biologicals, LLC

Phase 3

Florida, Indiana, Maine, Ohio, Washington

2026-05-11

Recruiting

A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

NCT07081997Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases

Ascendis Pharma Bone Diseases A/S

Phase 3

Colorado, Illinois, Minnesota, Nevada, New York, North Carolina, Texas, Washington

2026-05-07

Recruiting

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive

DrugsAsciminib single agent·ABL001

Novartis Pharmaceuticals

Phase 2

New Jersey, New York, Ohio, Washington

2026-04-28

Recruiting

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

NCT07342478CLL / SLL, CLL (Chronic Lymphocytic Leukemia), CLL, Refractory, CLL, Relapsed

DrugsRocbrutinib·Pirtobrutinib

Newave Pharmaceutical Inc

Phase 3

306

Illinois, Maryland, Nevada, Ohio, Pennsylvania, Washington

2026-04-23

Recruiting

A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)

NCT07227207Alpha-1 Antitrypsin Deficiency (AATD)

Tessera Therapeutics, Inc.

Phase 1/2

Florida, Massachusetts, Minnesota, South Carolina, Washington

2026-04-21

Recruiting

The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

NCT06796504Relapsing Remitting Multiple Sclerosis

SetPoint Medical Corporation

Not applicable

California, Georgia, Maryland, Minnesota, Texas, Washington, West Virginia, Wisconsin

2026-04-17

Recruiting

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

NCT07304154Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis

DrugsKITE-363·Fludarabine·Cyclophosphamide

Kite, A Gilead Company

Phase 1

California, New York, Utah, Washington

2026-04-10

Recruiting

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

NCT06964087Type I Diabetes

DrugOPT101

Op-T LLC

Phase 2

Alabama, California, Colorado, Illinois, Washington

2026-04-10

Recruiting

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

NCT07405164Von Hippel-Lindau Disease, Malignant Neoplasms

DrugsBelzutifan·Cabozantinib·Lenvatinib·Nivolumab

Merck Sharp & Dohme LLC

Phase 3

450

Massachusetts, Michigan, Pennsylvania, Tennessee, Texas, Washington

2026-03-23

Recruiting

Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis

NCT07234825Eosinophilic Esophagitis (EoE)

Kate Farms Inc

Not applicable

Washington

2026-03-18

Recruiting

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

NCT07291076Hepatocellular Carcinoma (HCC)

DrugsPumitamig·Yervoy·Ipilimumab

Bristol-Myers Squibb

Phase 1/2

198

California, Illinois, Michigan, New Jersey, New York, Oregon, Tennessee, Washington

2026-03-16

Recruiting

A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults

NCT07464314Influenza, Human+COVID-19

GlaxoSmithKline

Phase 1

225

Alabama, Arkansas, California, Florida, Georgia, Texas, Virginia, Washington

2026-03-09

Recruiting

HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor

NCT07396584Solid Tumors, Adult

Hutchmed

Phase 1/2

186

California, Florida, Georgia, Washington

2026-03-04

Recruiting

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

NCT07477639Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis, Multiple Sclerosis (MS) Primary Progressive

DrugBendamustine

Tr1X, Inc.

Phase 1/2

California, Kansas, Minnesota, Missouri, New York, North Carolina, Ohio, Washington

2026-03-01

Not yet open

EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization

NCT07313800Migraine Disorders, Refractory Migraine, Chronic Migraine

Cortex Neurovascular

Not applicable

Washington

2026-03-01

Recruiting

A Clinical Trial Comparing 2x/Day for 30-minutes Use of the Emanate Perio PODS Post-SRP to a Control Group Post-SRP.

NCT06914596Periodontitis (Stage 3)

McGuire Institute

Not applicable

California, Connecticut, Massachusetts, Nebraska, Texas, Virginia, Washington

2026-02-19

Recruiting

Ambulatory Long Length URodynamics Evaluation

NCT07425015Urology, Urinary Bladder, Overactive, Benign Prostatic Hyperplasia, Urodynamics

Bright Uro

Not applicable

101

Louisiana, Maryland, Missouri, Ohio, South Carolina, South Dakota, Texas, Washington

2026-02-17

Recruiting

ROME GS System Study

NCT07518004Diabetes, Diabetes Melletus, Type 1, Diabetes Mellitus, Type 2

Senseonics, Inc.

Not applicable

California, Texas, Washington

2026-02-12

Recruiting

Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM

NCT07296276Type 1 Diabetes Mellitus

i-SENS, Inc.

Not applicable

California, Georgia, Washington

2026-02-09

Not yet open

Evaluation of Effectiveness and Safety of Intense Pulsed Light Treatment for Chalazion

NCT07405138Chalazion

Lumenis Be Ltd.

Not applicable

New York, Washington

2026-02-04

Recruiting

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

NCT07121946Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)

LTZ Therapeutics, Inc.

Phase 1

California, Missouri, New York, Tennessee, Washington

2026-01-29

Recruiting

Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study

NCT07114718Congenital Heart Disease, Congenital Heart Disease (CHD)

Starlight Cardiovascular Inc

Not applicable

California, Colorado, Massachusetts, Ohio, Pennsylvania, Texas, Washington

2026-01-16

Recruiting

First-in-human Study of 7MW4911 in GI Cancer

NCT07216560GI Cancers

Drug7MW4911

Mabwell (Shanghai) Bioscience Co., Ltd.

Phase 1/2

200

Florida, Massachusetts, New York, Utah, Washington

2026-01-13

Recruiting

A Study of AZD0120 in Autoimmune Diseases

NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis

DrugAZD0120

AstraZeneca

Phase 1

Arizona, California, Illinois, Michigan, Missouri, New York, North Carolina, Washington

2026-01-09

Active, closed

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

NCT07285694Metastatic Castration Resistant Prostate Cancer (mCRPC)

Arsenal Biosciences, Inc.

Phase 1/2

190

California, Colorado, Iowa, Kansas, Minnesota, New York, Washington

2026-01-09

Recruiting

Metatranscriptomic Markers of Colonic Neoplasia

NCT07786818Colorectal Polyps

Viome

Observational

1,000

Washington

2025-12-20

Active, closed

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

NCT07225686Obesity, Obstructive Sleep Apnea

DrugMaridebart cafraglutide

Amgen

Phase 3

250

California, Florida, Georgia, New York, North Carolina, Ohio, Texas, Washington

2025-12-19

Active, closed

Study to Evaluate Xtresse Serum in Individuals With Thinning Hair

NCT07228156Thin Hair, Hair Loss, Alopecia, Thinning Hair

Restore Biologics Holdings, Inc. dba Xtressé

Not applicable

Florida, Maryland, Washington

2025-12-17

Recruiting

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

NCT07228247Solid Tumors, Adult

Hutchmed

Phase 1/2

147

Colorado, Florida, New Jersey, New York, Ohio, Washington

2025-12-16

Recruiting

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

NCT07222267Breast Cancer, Advanced Solid Tumor

DrugBG-75202

BeOne Medicines

Phase 1

Alabama, Connecticut, Missouri, Texas, Washington

2025-12-11

Recruiting

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

NCT07224373Multiple Sclerosis

AstraZeneca

Phase 1

Arizona, Colorado, District of Columbia, Missouri, New York, Ohio, Washington, Wisconsin

2025-12-09

Active, closed

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

NCT07287189Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases

DrugSAT-3247

Satellos Bioscience, Inc.

Phase 2

California, Colorado, Illinois, Massachusetts, Missouri, Ohio, Washington

2025-12-08

Active, closed

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

NCT07134088Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia

DrugBlinatumomab

Amgen

Phase 1/2

104

California, Pennsylvania, Tennessee, Washington

2025-12-08

Active, closed

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

NCT07116746Gout, Gouty Arthritis, Hyperuricemia, Gout Chronic

Arthrosi Therapeutics

Phase 2

Florida, Mississippi, North Carolina, Pennsylvania, Texas, Washington

2025-12-03

Recruiting

A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)

NCT07116031Chronic Graft Versus Host Disease

DrugBelumosudil

Sanofi

Phase 2

California, District of Columbia, Georgia, Massachusetts, New York, Texas, Washington

2025-12-02

Recruiting

Effects of NLS-133, a Potential Non-Hormonal "On-Demand" Male Contraceptive

NCT07393334Male Contraception, Semen Volume, Sperm Motility

Next Life Sciences

Phase 2

Washington

2025-12-02

Recruiting

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

NCT07176650Hepatocellular Carcinoma (HCC)

DrugsYervoy·Opdivo

Shanghai Henlius Biotech

Phase 1

246

California, Florida, Tennessee, Texas, Washington

2025-11-25

Active, closed

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

NCT07226765Obstructive Sleep Apnea

DrugMaridebart cafraglutide

Amgen

Phase 3

250

California, Florida, Georgia, New York, North Carolina, Ohio, Texas, Washington

2025-11-25

Recruiting

Endovascular Repair With Fenestrated TREO Stent-Graft System in AAA

NCT07026877Abdominal Aortic Aneurysms (AAA)

Bolton Medical

Not applicable

Colorado, Florida, Massachusetts, Missouri, New York, Texas, Washington

2025-11-18

Recruiting

Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis

NCT07270601MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, NAFLD - Non-Alcoholic Fatty Liver Disease

ContextVision AB

Not applicable

110

Washington

2025-11-17

Active, closed

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

NCT07074886Multiple Sclerosis

Hoffmann-La Roche

Phase 2

193

California, Colorado, Florida, Maryland, Massachusetts, New York, Tennessee, Washington

2025-11-13

Recruiting

PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

NCT06157151Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, Recurrent Cervical Carcinoma

DrugPembrolizumab

Precigen, Inc

Phase 2

Arkansas, Maryland, Washington

2025-11-11

Recruiting

A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

NCT06699121Primary Sclerosing Cholangitis (PSC)

LISCure Biosciences

Phase 2

California, Colorado, Iowa, Maryland, Minnesota, Tennessee, Washington

2025-11

Recruiting

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

NCT07205822Breast Cancer

DrugDato-DXd

AstraZeneca

Phase 3

100

Florida, Indiana, Nebraska, New York, Texas, Washington

2025-10-30

Recruiting

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

NCT07217067Atrial Fibrillation

Novartis Pharmaceuticals

Phase 2

165

Mississippi, New Jersey, New York, North Carolina, Utah, Washington

2025-10-28

Active, closed

Clinical Performance of Capillary Blood Samples Collected Using the Tasso+ Serum Gel Capillary Blood Collection System for Clinical Chemistry Testing of 14 Analytes on an Abbott Alinity Analyzer

NCT07260799Serum Analytes

Tasso Inc.

Observational

150

Florida, Washington

2025-10-25

Recruiting

A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy

NCT07127978Duchene Muscular Dystrophy

ITF Therapeutics LLC

Observational

300

Arkansas, District of Columbia, Illinois, Massachusetts, New York, North Carolina, Oregon, Washington

2025-10-23

Recruiting

Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue

NCT07229430Skin Laxity (Submental and Neck), Facial Skin Laxity, Submental Tissue Laxity

CLASSYS Inc.

Not applicable

273

California, North Carolina, Tennessee, Washington

2025-10-16

Recruiting

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

NCT07006727Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma

Novartis Pharmaceuticals

Phase 1

116

Iowa, Massachusetts, Michigan, Washington

2025-10-16

Recruiting

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

NCT07206056Progressive Metastatic Castrate Resistant Prostate Cancer

DrugLuxdegalutamide

Novartis Pharmaceuticals

Phase 1/2

188

Colorado, Florida, Georgia, Kansas, Massachusetts, North Carolina, Ohio, Washington

2025-10-15

Recruiting

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

NCT07160725Solid Tumours

DrugPumitamig

Bristol-Myers Squibb

Phase 1/2

540

California, Pennsylvania, South Dakota, Texas, Utah, Washington

2025-10-15

Recruiting

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

NCT06997588PIK3CA-related Overgrowth Spectrum (PROS)

DrugAlpelisib

Novartis Pharmaceuticals

Phase 2

140

Missouri, North Carolina, Ohio, Oregon, Pennsylvania, Texas, Washington

2025-10-09

Active, closed

Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

NCT07219121Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis, Kidney Transplant

DrugSparsentan

Travere Therapeutics, Inc.

Phase 4

Alabama, New York, North Carolina, Ohio, Texas, Washington, Wisconsin

2025-10-07

Recruiting

Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants

NCT06613568End Stage Kidney Disease

Diality Inc.

Not applicable

California, New York, Tennessee, Texas, Washington

2025-10-06

Recruiting

Pivotal Study on the NOVABLOC System for Patients Undergoing Primary Total Knee Arthroplasty

NCT07191067Pain

Synaptrix, Inc.

Not applicable

120

Alabama, New York, North Carolina, Oregon, Washington

2025-09-30

Recruiting

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

NCT07197866Multiple System Atrophy

DrugEmrusolmin

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

200

California, Florida, Illinois, Kansas, New York, North Carolina, Pennsylvania, Washington

2025-09-30

Active, closed

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

NCT07160335Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma

DrugsUS-sourced Keytruda·Pembrolizumab

Shanghai Henlius Biotech

Phase 1

174

California, Florida, Texas, Washington

2025-09-26

Active, closed

A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer

NCT06396091Metastatic Pancreatic Adenocarcinoma

DrugsZolbetuximab·MFOLFIRINOX

Astellas Pharma Global Development, Inc.

Phase 1

Washington

2025-09-24

Recruiting

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

NCT06760546Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia

DrugSetmelanotide

Rhythm Pharmaceuticals, Inc.

Phase 3

Alabama, Colorado, Illinois, Massachusetts, Minnesota, New York, Pennsylvania, Washington

2025-09-23

Recruiting

Study of Student Flourishing

NCT07259746Healthy

Flourish Science, Inc.

Not applicable

2,500

California, Colorado, Hawaii, Kansas, Rhode Island, Washington, Wisconsin

2025-09-22

Active, closed

GSI Cardiac on Revolution Apex - US

NCT06702917Coronary Computed Tomographic Angiography, Myocardial Infarction (MI), Cardiac Catheterization

GE Healthcare

Observational

Washington

2025-09-10

Recruiting

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

NCT06855771Carcinoma, Non-Small-Cell Lung

DrugsNavlimetostat·Iza-bren

Bristol-Myers Squibb

Phase 2

182

Alaska, Massachusetts, Michigan, Missouri, New York, Ohio, Oregon, Washington

2025-09-09

Active, closed

Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology)

NCT07120945Uterine Fibroids (UF), Menstrual Disorders, Adenomyosis of Uterus, Endometriosis

Medtronic - MITG

Not applicable

Florida, North Carolina, Pennsylvania, Washington

2025-08-28

Active, closed

A Study Evaluating TRIV-509 in Atopic Dermatitis

NCT07167758Atopic Dermatitis

Triveni Bio

Phase 2

California, Florida, Indiana, Pennsylvania, Texas, Washington

2025-08-26

Recruiting

SLV-324 Treatment of Metastatic Solid Tumors

NCT07108114Metastatic Solid Tumors

Solve Therapeutics

Phase 1

California, Missouri, Ohio, Pennsylvania, Texas, Washington

2025-08-25

Recruiting

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06896916Multiple Myeloma

DrugsEtentamig·Iberdomide

AbbVie

Phase 1

135

California, Colorado, Missouri, New Jersey, New York, North Carolina, Washington

2025-08-07

Recruiting

A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

NCT07021898Metastatic Solid Tumors

Erasca, Inc.

Phase 1

200

Tennessee, Texas, Washington

2025-08-06

Recruiting

OM336 in Autoimmune Cytopenias

NCT07083960AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia, ITP - Immune Thrombocytopenia

Lakefront Biotherapeutics West LLC

Phase 1

California, District of Columbia, Michigan, Washington

2025-08-01

Recruiting

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer

DrugMRG007

ArriVent BioPharma, Inc.

Phase 1

572

California, Colorado, Florida, Tennessee, Texas, Virginia, Washington

2025-07-25

Active, closed

A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG

NCT06892288Phosphomannomutase 2 Deficiency, PMM2-CDG

Glycomine, Inc.

Phase 2/3

Minnesota, New York, Pennsylvania, Washington

2025-07-09

Recruiting

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

NCT06915025Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma

DrugsIMNN-001·Niraparib·Olaparib·Paclitaxel

Imunon

Phase 3

500

Florida, Louisiana, Minnesota, Missouri, Oregon, South Dakota, Tennessee, Washington

2025-07-09

Recruiting

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

NCT07082920Prostatic Neoplasms

DrugsARX517·JNJ-87189401·Pasritamig

Janssen Research & Development, LLC

Phase 1

140

Florida, New York, Ohio, Washington

2025-07-07

Recruiting

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

NCT06863272Castration-Resistant Prostatic Cancer, Metastasis

DrugsOpevesostat·Ifinatamab Deruxtecan·Abiraterone·Enzalutamide

Merck Sharp & Dohme LLC

Phase 1/2

360

California, District of Columbia, Michigan, New York, Pennsylvania, Tennessee, Washington

2025-07-03

Not yet open

EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

NCT06748872Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma

Medigene AG

Phase 1

Washington

2025-07-01

Recruiting

A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults

NCT06937931Cervical Dystonia

DrugCorabotase

Ipsen

Phase 2

132

Arizona, California, Florida, Georgia, Illinois, Michigan, New York, Washington

2025-06-30

Active, closed

CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen

NCT06699836Metastatic Colorectal Cancer (mCRC)

DrugsLeronlimab·Keytruda·Pembrolizumab

CytoDyn, Inc.

Phase 2

California, District of Columbia, Kentucky, Nebraska, Pennsylvania, Washington

2025-06-16

Recruiting

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

NCT06885034Gastrointestinal Neoplasms

DrugRisvutatug rezetecan

GlaxoSmithKline

Phase 1/2

451

California, Colorado, New York, North Carolina, Texas, Washington, Wisconsin

2025-06-11

Recruiting

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

NCT06993844Advanced Solid Tumors, Advanced Breast Cancer

DrugFulvestrant

Ensem Therapeutics

Phase 1/2

233

California, Connecticut, Massachusetts, North Carolina, Texas, Virginia, Washington

2025-06-10

Recruiting

Contour Neurovascular System™ ContiNued Access Investigational Device EXempTion (IDE) Trial (NEXT Trial)

NCT06693011Cerebral Aneurysms

Cerus Endovascular, Inc.

Not applicable

250

Illinois, Kansas, New York, North Carolina, Pennsylvania, South Carolina, Washington

2025-06-10

Active, closed

A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia

NCT06953583Friedreich Ataxia

DrugsOmaveloxolone·Skyclarys

Biogen

Phase 3

255

California, Florida, Pennsylvania, Tennessee, Virginia, Washington

2025-06-09

Recruiting

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

NCT06961006Malignant Melanoma

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

160

Arkansas, California, New Jersey, Virginia, Washington

2025-05-29

Active, closed

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

NCT06782373VEXAS, VEXAS Syndrome

DrugPacritinib

Swedish Orphan Biovitrum

Phase 2

156

Arizona, Massachusetts, Minnesota, New York, Ohio, Texas, Utah, Washington

2025-05-28

Recruiting

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

NCT06682793Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer)

A2 Biotherapeutics Inc.

Phase 1/2

240

Arizona, California, Florida, Minnesota, Missouri, New York, Ohio, Washington

2025-05-22

Recruiting

SLV-154 Treatment of Advanced Cancers

NCT06771219Advanced Cancer, Advanced Solid Tumor, Metastatic Cancer

Solve Therapeutics

Phase 1

250

California, Missouri, New Jersey, New York, Ohio, Pennsylvania, Texas, Washington

2025-05-14

Active, closed

Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])

NCT06717438Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder

Shionogi

Phase 2

Illinois, Massachusetts, Washington

2025-05-13

Recruiting

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

NCT06801236Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)

Acerand Therapeutics (Hong Kong) Limited

Phase 1

California, Florida, Maryland, Massachusetts, Minnesota, Nebraska, South Carolina, Washington

2025-05-12

Recruiting

Evaluating Therapeutic Electrical Stimulation to Improve Nerve Healing After Surgical Repair of Digital Nerve Injuries

NCT06867185Digital Nerve Injury, Nerve Injury, Nerve Reconstruction, Nerve Trauma

Checkpoint Surgical Inc.

Not applicable

Indiana, Missouri, Ohio, Washington

2025-04-24

Recruiting

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06673017Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer

PanTher Therapeutics

Phase 1

California, Florida, Michigan, New York, Texas, Washington

2025-04-14

Recruiting

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

NCT06834282AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia

DrugsMesna·Fludarabine·Cyclophosphamide

CERo Therapeutics Holdings, Inc.

Phase 1

California, Colorado, Tennessee, Texas, Washington

2025-04-07

Recruiting

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer

DrugsRibociclib·Fulvestrant

Novartis Pharmaceuticals

Phase 1/2

280

California, Florida, Massachusetts, Missouri, New York, Tennessee, Texas, Washington

2025-04-03

Active, closed

Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults

NCT06869187Bipolar Disorder Depression

DrugABX-002

Autobahn Therapeutics, Inc.

Phase 2

California, Connecticut, Florida, Illinois, Massachusetts, New Jersey, New York, Washington

2025-03-28

Recruiting

MagDI U.S. Registry

NCT06928545Anastomosis, Surgical, Internal Hernia, Bowel Obstruction

GT Metabolic Solutions, Inc.

Observational

106

California, Florida, Kentucky, Louisiana, North Carolina, Washington

2025-03-28

By invitation

Study Evaluating Xtressé Gummy Supplement in Women With Self-Perceived Thinning Hair

NCT07224555Hair Thinning

Restore Biologics Holdings, Inc. dba Xtressé

Not applicable

Florida, Georgia, Maryland, Washington

2025-03-27

Recruiting

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

NCT06826196Alopecia Areata (AA)

Aldena Therapeutics

Phase 1/2

California, Indiana, Massachusetts, Washington

2025-03-24

Recruiting

A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

NCT06803680Advanced Solid Tumor, Metastatic Solid Tumor

BeOne Medicines

Phase 1

Florida, Pennsylvania, South Dakota, Texas, Washington

2025-03-18

Recruiting

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

NCT06528301Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL), Lymphoma, Large B-Cell, Diffuse (DLBCL), Chronic Lymphocytic Leukemia (CLL)

DrugsRapamycin·Sirolimus

Umoja Biopharma

Phase 1

106

California, Illinois, Missouri, Nebraska, Ohio, Washington

2025-03-10

Recruiting

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

NCT06517875Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

DrugsMomelotinib·Reblozyl·Luspatercept

GlaxoSmithKline

Phase 2

Michigan, New York, Tennessee, Texas, Washington

2025-02-28

Recruiting

Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant

NCT06938867E Coli Infections, Allogenic Transplant Patients

SNIPR Biome Aps.

Phase 1/2

California, Maryland, Minnesota, New York, Pennsylvania, Texas, Washington

2025-02-25

Recruiting

A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

NCT06809400Parkinson Disease

Eli Lilly and Company

Phase 1

127

California, Florida, Michigan, Texas, Washington

2025-02-18

Recruiting

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

NCT06697197Advanced Solid Tumors

DrugsNivolumab and rHuPH20·Opdualag·Bevacizumab

Bristol-Myers Squibb

Phase 1/2

413

California, Colorado, New Jersey, New York, North Carolina, Washington

2025-02-17

Active, closed

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

NCT06255028Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis

DrugAldesleukin

Century Therapeutics, Inc.

Phase 1

California, Illinois, Texas, Utah, Washington

2025-02-06

Recruiting

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

NCT06756932Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer

DrugsBGB-43395·Fulvestrant

BeOne Medicines

Phase 1

120

Iowa, Texas, Washington

2025-02-04

Recruiting

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

NCT06697184Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL

DrugsSonrotoclax·Zanubrutinib

BeOne Medicines

Phase 1/2

258

Florida, Indiana, Kansas, Massachusetts, Missouri, Washington

2025-01-23

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

NCT06609005Advanced Metastatic Castration Resistant Prostate Cancer

Shenzhen Ionova Life Sciences Co., Ltd.

Phase 1/2

Arizona, California, Texas, Virginia, Washington

2025-01-23

Recruiting

Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06786624Major Depressive Disorder

DrugNBI-1065845

Neurocrine Biosciences

Phase 3

200

Arkansas, California, Florida, Massachusetts, New York, Ohio, Texas, Washington

2025-01-22

Recruiting

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

NCT06274788Parenteral Nutrition Associated Liver Disease (PNALD), Essential Fatty Acid Deficiency, Malnutrition, Pediatric ALL

Fresenius Kabi

Observational

California, Illinois, Massachusetts, Ohio, Oklahoma, Tennessee, Texas, Washington

2024-12-15

Recruiting

A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

NCT06625593Advanced Solid Tumor

BeOne Medicines

Phase 1

168

California, Connecticut, Minnesota, Texas, Washington, Wisconsin

2024-12-09

Active, closed

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

NCT06534983Muscle-invasive Urothelial Carcinoma

DrugsAutogene cevumeran·Opdivo·Nivolumab

Hoffmann-La Roche

Phase 2

New Jersey, New York, Washington

2024-12-09

Recruiting

Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion

NCT04679844Degenerative Disc Disease, Spine Fusion, Back Pain

Kuros Biosurgery AG

Not applicable

California, Michigan, Missouri, Pennsylvania, Tennessee, Washington

2024-12-06

Recruiting

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

NCT06651281Crohn Disease, Colitis, Ulcerative

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,380

Connecticut, Michigan, Missouri, New York, Texas, Virginia, Washington

2024-11-25

Recruiting

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

NCT06613100Prostate Cancer

DrugXaluritamig

Amgen

Phase 1

California, Missouri, Ohio, Pennsylvania, South Carolina, Washington, Wisconsin

2024-11-25

Recruiting

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

NCT06589440Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

DrugsBalstilimab·Botensilimab

Stingray Therapeutics

Phase 2

New Jersey, Texas, Washington

2024-11-20

Recruiting

A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age

NCT06702449Urinary Tract Infections

GlaxoSmithKline

Phase 1/2

448

Kansas, New Jersey, New York, Texas, Washington

2024-11-19

Active, closed

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

NCT06577935Postmenopausal Osteoporosis

Angitia Biopharmaceuticals

Phase 2

379

Alabama, Georgia, New Mexico, Pennsylvania, Washington

2024-10-31

Active, closed

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

NCT06602193Parkinson Disease

Denali Therapeutics Inc.

Phase 2

California, Florida, Massachusetts, New York, Washington

2024-10-24

Active, closed

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

NCT06643728Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 2

252

Alabama, California, Florida, Hawaii, Illinois, Mississippi, Pennsylvania, Washington

2024-10-21

Recruiting

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer

Novartis Pharmaceuticals

Phase 1

162

Alabama, California, Florida, Massachusetts, Michigan, Minnesota, Texas, Washington

2024-10-15

Recruiting

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

NCT06663319Colorectal Neoplasms, Gastrointestinal Neoplasms

DrugsFolfiri·Folfox·Bevacizumab

Janssen Research & Development, LLC

Phase 1

260

Arizona, Colorado, Florida, Indiana, Michigan, Washington

2024-10-15

Active, closed

Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)

NCT05417789TGCT

DrugEmactuzumab

SynOx Therapeutics Limited

Phase 3

128

California, Ohio, Texas, Washington

2024-10-09

Recruiting

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

NCT06598306Extensive Stage Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 1

220

California, Illinois, Michigan, South Dakota, Texas, Washington

2024-10-07

Active, closed

Assessment of Heart Rate Measurement Accuracy for the PreemptiveAI SDK in Adults

NCT06696339Heart Rate in the General Public

PreemptiveAI, Inc

Observational

100

Washington

2024-10-03

By invitation

Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients

NCT06657859Pmm2-CDG, Phosphomannomutase 2 Deficiency

Glycomine, Inc.

Phase 2

Minnesota, New York, Pennsylvania, Washington

2024-09-30

Active, closed

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

NCT06555796Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer

DrugXaluritamig

Amgen

Phase 1

Minnesota, New York, North Carolina, Oregon, Pennsylvania, Texas, Washington

2024-09-23

Recruiting

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

NCT06542250B-cell Malignancies

DrugAZD5492

AstraZeneca

Phase 1/2

174

California, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Texas, Washington

2024-09-18

Recruiting

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

NCT06140524Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 2

116

Maryland, Massachusetts, Michigan, New York, Pennsylvania, Washington

2024-09-16

Active, closed

A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)

NCT06503731Antibody-mediated Rejection

argenx

Phase 2

Alabama, California, Illinois, Nebraska, North Carolina, Ohio, Virginia, Washington

2024-08-30

Recruiting

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

NCT06500884Multiple Myeloma

DrugsRamantamig·Talquetamab

Janssen Research & Development, LLC

Phase 2

210

California, Colorado, Connecticut, New York, North Carolina, Ohio, Virginia, Washington

2024-08-26

Active, closed

Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

NCT06462183Adenoid Cystic Carcinoma, Colorectal Cancer

DrugLenvatinib

Rgenta Therapeutics Inc

Phase 1

105

Massachusetts, Michigan, New York, Texas, Virginia, Washington

2024-08-19

Recruiting

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

NCT06540833Psychotic Disorders, Alzheimer Disease

DrugITI-1284

Intra-Cellular Therapies, Inc.

Phase 2

370

California, Florida, Georgia, New Jersey, North Carolina, Texas, Washington

2024-08-15

Recruiting

SMP-3124LP in Adults With Advanced Solid Tumors

NCT06526819Solid Tumor

Sumitomo Pharma America, Inc.

Phase 1/2

120

California, Colorado, Florida, Illinois, Ohio, Tennessee, Texas, Washington

2024-08-14

Recruiting

Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)

NCT06212193Tricuspid Regurgitation, Tricuspid Regurgitation Functional

Innoventric LTD

Not applicable

California, Michigan, Minnesota, New York, Ohio, Pennsylvania, Tennessee, Washington

2024-08-05

Active, closed

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

NCT06147037Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer

AstraZeneca

Phase 1

California, Illinois, Nebraska, Ohio, Texas, Washington

2024-07-31

Recruiting

Study of Enhanced Programming Stimulation with the Enterra® Therapy System

NCT06560307Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus

Enterra Medical, Inc.

Not applicable

Florida, Kentucky, Michigan, Missouri, Oregon, Washington

2024-07-25

Recruiting

A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

NCT06046495Non-Small Cell Lung Cancer

DrugAndamertinib

Avistone Biotechnology Co., Ltd.

Phase 1

California, Kentucky, Nebraska, New York, Tennessee, Washington

2024-07-08

Recruiting

TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

NCT06088888Chronic Myelogenous Leukemia

DrugTGRX-678

Shenzhen TargetRx Co., Ltd.

Phase 1

Texas, Washington

2024-07-02

Recruiting

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06307795Locally Advanced or Metastatic Solid Tumors

DrugANS014004

Avistone Biotechnology Co., Ltd.

Phase 1

California, Colorado, Florida, Michigan, New York, Texas, Virginia, Washington

2024-06-24

Recruiting

KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure

NCT05879835Pediatric Intestinal Failure

SterileCare Inc.

Not applicable

124

Massachusetts, Nebraska, New York, North Carolina, Ohio, Texas, Washington

2024-06-21

Recruiting

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

NCT06501196Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia

DrugsVenclyxto·Venclexta·Venetoclax

BlossomHill Therapeutics

Phase 1

170

California, Florida, Illinois, New York, Ohio, Tennessee, Texas, Washington

2024-06-19

Active, closed

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

NCT06472076Lung Cancer, Non-Small Cell

DrugsBelrestotug·Dostarlimab·Pembrolizumab

GlaxoSmithKline

Phase 3

Florida, Hawaii, Kentucky, Nebraska, Tennessee, Texas, Washington

2024-06-10

Recruiting

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

NCT05703971Small Cell Lung Cancer Extensive Stage

DrugsQuaratusugene ozeplasmid·Tecentriq·Atezolizumab

Genprex, Inc.

Phase 1/2

Colorado, Missouri, Ohio, Oregon, Texas, Virginia, Washington

2024-05-09

Recruiting

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

NCT06164730Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease

DrugVERVE-102

Verve Therapeutics, Inc.

Phase 1

Alabama, California, Florida, Indiana, North Carolina, Pennsylvania, Texas, Washington

2024-04-30

Recruiting

A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product

NCT05768269Hematological Malignancy, Solid Tumor Malignancy

Century Therapeutics, Inc.

Observational

375

Arizona, California, Maryland, Michigan, North Carolina, Ohio, Washington

2024-04-29

Active, closed

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

NCT06294236Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

DrugsSC291·Fludarabine·Cyclophosphamide

Sana Biotechnology

Phase 1

Colorado, Georgia, Maryland, Massachusetts, Washington

2024-04-29

Active, closed

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)

NCT06285422Non Hodgkin's Lymphoma, Large B-cell Lymphoma

DrugsFludarabine·Cyclophosphamide

Sana Biotechnology

Phase 1

Kansas, Washington

2024-04-18

Recruiting

Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma

NCT06149910Multiple Myeloma, Multiple Myeloma Without Mention of Remission

All4Cure

Observational

450

Washington

2024-04-18

Recruiting

BostonGene and Exigent Genomic INsight Study

NCT06272864Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma

BostonGene

Observational

400

Arkansas, California, Indiana, New Mexico, Oklahoma, Texas, Washington

2024-04-08

Recruiting

A Study of IBI363 in Subjects with Advanced Solid Malignancies

NCT06281678Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer

DrugLenvatinib

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

178

California, Florida, Kansas, Michigan, Texas, Washington

2024-04-08

Recruiting

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

NCT06462365Hematologic Malignancy, GvHD, GVHD,Acute, GVHD, Chronic

DrugTRX103

Tr1X, Inc.

Phase 1

California, Massachusetts, Minnesota, New York, Washington

2024-04-08

Recruiting

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

NCT06158854Immunoglobulin Light Chain (AL) Amyloidosis

DrugEtentamig

AbbVie

Phase 1/2

Florida, Massachusetts, Minnesota, New York, North Carolina, Oregon, Tennessee, Washington

2024-04-01

Recruiting

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

NCT06150664Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma

Compass Therapeutics

Phase 1

Florida, Georgia, Indiana, Massachusetts, New York, Tennessee, Washington

2024-03-19

Active, closed

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

NCT06334432Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer

Nuvation Bio Inc.

Phase 1/2

466

Michigan, New Jersey, New York, North Carolina, Texas, Utah, Virginia, Washington

2024-03-14

Active, closed

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

NCT06105021Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor

Affini-T Therapeutics, Inc.

Phase 1/2

100

California, Connecticut, New York, Oregon, Tennessee, Texas, Washington, Wisconsin

2024-03-06

Active, closed

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

NCT06239467Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation

DrugsAtirmociclib·Tucatinib·Ribociclib·Fulvestrant

OnKure, Inc.

Phase 1

200

California, Colorado, Massachusetts, Nevada, New York, Tennessee, Virginia, Washington

2024-02-26

Active, closed

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

NCT05458674Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer

DrugsTucatinib·Eribulin·Herceptin·Trastuzumab

Criterium, Inc.

Phase 2

Colorado, District of Columbia, New Mexico, Washington, Wisconsin

2024-01-30

Recruiting

A Study of KK2269 in Adult Participants With Solid Tumors

NCT06266299Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugDocetaxel

Kyowa Kirin Co., Ltd.

Phase 1

101

Arizona, California, Florida, Missouri, Texas, Washington

2024-01-18

Active, closed

Using Signos mHealth Platform in Adults for Weight Management

NCT06214221Overweight and Obesity, Metabolic Syndrome, Weight Loss

Signos Inc

Not applicable

380

Arizona, California, Florida, Texas, Washington

2024-01-02

Recruiting

Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy

NCT05905328Cytokine Release Syndrome

CytoAgents, Inc.

Phase 1/2

California, Georgia, Massachusetts, North Carolina, Pennsylvania, Washington

2023-12-28

Active, closed

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

NCT06099782Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma

Drugs) Berahyaluronidase alfa·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

147

Alabama, Alaska, Arkansas, California, Florida, Georgia, Washington

2023-12-26

Active, closed

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

NCT06140836Carcinoma, Non-Small-Cell Lung

DrugsRepotrectinib·Crizotinib

Bristol-Myers Squibb

Phase 3

190

Iowa, Massachusetts, New York, Washington

2023-12-21

Recruiting

Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c

NCT06185192Diabetes

Viome

Not applicable

100

Washington

2023-12-13

Recruiting

A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

NCT05761223Advanced Solid Tumor

DrugPembrolizumab

1ST Biotherapeutics, Inc.

Phase 1/2

151

Ohio, Texas, Virginia, Washington

2023-12-13

Not yet open

Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer

NCT05794659Advanced Ovarian Cancer

DrugsAST-201·RhuGM-CSF·Sargramostim·Leukine

Aston Sci. Inc.

Phase 2

Washington

2023-11-15

Active, closed

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma

NCT06079164Relapsed/Refractory Large B-cell Lymphoma

DrugsKITE-197·Fludarabine·Cyclophosphamide

Kite, A Gilead Company

Phase 1

Florida, Illinois, Tennessee, Texas, Washington

2023-11-09

Active, closed

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

NCT06101134Melanoma

DrugsPhesgo·Relatlimab·Opdivo·Nivolumab

Bristol-Myers Squibb

Phase 2

100

Alaska, Arizona, California, Georgia, Kentucky, New Mexico, Washington

2023-11-06

Recruiting

ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions

NCT06085833Breast Cancer

ARTIDIS AG

Not applicable

2,706

Texas, Washington

2023-11-02

Recruiting

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

NCT06047379Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer

DrugsFOLFIRI Protocol·Zirabev·Mvasi·Regorafenib

Neonc Technologies, Inc.

Phase 1/2

134

California, Florida, Massachusetts, Tennessee, Texas, Washington

2023-11-01

Active, closed

Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant

NCT06163404Nasal Septal Deviation, Nasal Airway Obstruction

Spirair, Inc

Not applicable

102

Alabama, California, Kentucky, Louisiana, New York, Pennsylvania, Washington

2023-11-01

Recruiting

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06067841Metastatic Castration-resistant Prostate Cancer

Bristol-Myers Squibb

Phase 1

140

California, Florida, Massachusetts, New York, North Carolina, Texas, Washington

2023-10-18

Active, closed

J-Valve TF Early Feasibility Study

NCT06034028Aortic Valve Disease, Aortic Valve Insufficiency, Aortic Regurgitation

JC Medical, Inc., an affiliate of Edwards Lifesciences LLC

Not applicable

Arizona, District of Columbia, Illinois, Louisiana, New York, Ohio, Texas, Washington

2023-10-16

Recruiting

Viome Nutritional Programs to Improve Clinical Outcomes for Metabolic Conditions

NCT05564273Metabolic Health

Viome

Not applicable

150

Washington

2023-10-13

Active, closed

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

NCT05911295Urothelial Carcinoma

DrugsDisitamab Vedotin·Keytruda·Gemcitabine·Cisplatin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

412

Arizona, California, Minnesota, Pennsylvania, Texas, Washington

2023-09-22

Recruiting

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)

DrugsElotuzumab·Linvoseltamab·Pomalidomide·Dexamethasone

Regeneron Pharmaceuticals

Phase 3

410

California, Florida, Kentucky, New York, North Carolina, Oregon, Texas, Washington

2023-09-18

Recruiting

PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma

NCT05956457Multiple Myeloma, Relapsed Hematologic Malignancy

Pack Health

Not applicable

100

Washington

2023-09-15

Recruiting

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

NCT06034275Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome

Vincerx Pharma, Inc.

Phase 1

Alabama, Ohio, Tennessee, Texas, Washington

2023-09-13

Recruiting

A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

NCT05797805Advanced Hepatocellular Carcinoma

DrugsCabozantinib·Lenvatinib

Iterion Therapeutics

Phase 1/2

178

California, Florida, Illinois, North Carolina, Texas, Washington

2023-09-13

Active, closed

Azeliragon in MGMT Unmethylated Glioblastoma

NCT05986851Glioblastoma

Cantex Pharmaceuticals

Phase 2

Colorado, Florida, Michigan, Missouri, New York, Oklahoma, Utah, Washington

2023-09-12

Recruiting

A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (GLOBALIGHT)

NCT06351605Dry Age-related Macular Degeneration

LumiThera, Inc.

Observational

500

California, Ohio, South Carolina, Texas, Washington

2023-09-01

By invitation

Prediction of REsponse to Depression Interventions Using Clinical and TD-fNIRS Measurements

NCT06002100Depression, Major Depressive Disorder

Kernel

Observational

540

California, Ohio, Washington

2023-08-14

Recruiting

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

NCT05997615Hormone-refractory Prostate Cancer

Astellas Pharma Global Development, Inc.

Phase 1

437

California, Texas, Virginia, Washington

2023-08-10

By invitation

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)

NCT05796440Growth Hormone Deficiency

DrugLUM-201

Lumos Pharma

Phase 2

Iowa, Massachusetts, Missouri, South Carolina, Texas, Washington

2023-08-01

Recruiting

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

NCT05808634Advanced Adenocarcinoma

BioAtla, Inc.

Phase 1

168

California, Connecticut, Illinois, Michigan, Ohio, Washington

2023-07-14

Recruiting

A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations

NCT05788536Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

Regeneron Pharmaceuticals

Phase 1/2

California, Florida, Massachusetts, New York, Ohio, Washington, Wisconsin

2023-06-27

Recruiting

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

NCT05780034Relapsed/Refractory B-cell Malignancies

Accutar Biotechnology Inc

Phase 1

Colorado, Florida, North Carolina, Ohio, Oregon, Tennessee, Texas, Washington

2023-06-20

Recruiting

A Retrospective Study to Characterize Participants With Propionic Acidemia

NCT05769621Propionic Acidemia

ModernaTX, Inc.

Observational

California, Maryland, Michigan, Pennsylvania, Texas, Washington

2023-06-16

Recruiting

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

NCT05648591Schizophrenia, Bipolar I Disorder

DrugIloperidone

Vanda Pharmaceuticals

Phase 4

100

Alabama, Arkansas, Colorado, Georgia, North Carolina, Ohio, Washington

2023-05-24

Active, closed

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

NCT05663866Carcinoma, Non-Small-Cell Lung

DrugsMontelukast·Lazertinib·Amivantamab·Methotrexate

Janssen Research & Development, LLC

Phase 2

California, Virginia, Washington

2023-05-18

Recruiting

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

NCT05765812Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III

DrugTemozolomide

Debiopharm International SA

Phase 1/2

116

Illinois, New York, Texas, Utah, Washington

2023-05-15

Active, closed

A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

NCT05230459Limb Girdle Muscular Dystrophy, Limb-Girdle Muscular Dystrophy Type 2, LGMD2I, Muscular Dystrophy

AskBio Inc

Phase 1/2

California, Iowa, Kansas, Maryland, Virginia, Washington

2023-05-15

Active, closed

Study of GS-4528 in Adults With Solid Tumors

NCT05840224Solid Tumor

DrugZimberelimab

Gilead Sciences

Phase 1

182

Washington

2023-05-11

Recruiting

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

NCT05855083Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation

Omeros Corporation

Phase 2

California, Florida, Massachusetts, Missouri, New York, Texas, Washington

2023-05-01

Active, closed

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

NCT05804045Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath

DrugPimicotinib

Abbisko Therapeutics Co, Ltd

Phase 3

California, Michigan, New York, Ohio, Texas, Washington

2023-04-27

Recruiting

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

NCT05732103Acute Myeloid Leukemia, Myelodysplastic Syndromes

Chordia Therapeutics, Inc.

Phase 1/2

225

Arizona, Florida, Illinois, Minnesota, New York, Texas, Virginia, Washington

2023-04-25

Active, closed

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

NCT05557591Advanced Non-Small Cell Lung Cancer

DrugsBNT116·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

California, Kentucky, New Mexico, New York, North Carolina, Texas, Virginia, Washington

2023-04-21

Active, closed

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

NCT05539430Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer

Legend Biotech USA Inc

Phase 1

Florida, Michigan, New Jersey, New York, North Carolina, Oregon, Tennessee, Washington

2023-04-18

Active, closed

Open Label Optimization Study

NCT05819021Major Depressive Disorder

Magnus Medical

Observational

1,000

California, Massachusetts, New York, Washington

2023-04-06

Active, closed

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

NCT05683457Cytomegalovirus Infection

ModernaTX, Inc.

Phase 2

Massachusetts, Missouri, Washington

2023-04-05

Active, closed

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

NCT05624554Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsNemtabrutinib·Riabni·Ruxience·Truxima

Merck Sharp & Dohme LLC

Phase 3

300

Arkansas, Florida, Mississippi, Washington

2023-03-16

Recruiting

Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)

NCT05776069Von Willebrand Diseases

DrugVGA039

Vega Therapeutics, Inc

Phase 1/2

116

California, Colorado, Georgia, North Carolina, Pennsylvania, Tennessee, Texas, Washington

2023-03-16

Recruiting

Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors

NCT05784688Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer

DrugsTU2218·Keytruda·Pembrolizumab

TiumBio Co., Ltd.

Phase 1/2

140

Texas, Washington

2023-03-10

Active, closed

Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma

NCT05673083Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory, Multiple Myeloma With Failed Remission

All4Cure

Observational

200

Arkansas, Florida, Iowa, New York, Oklahoma, Texas, Washington

2023-03-01

Active, closed

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

NCT05548127Breast Cancer

DrugsVepdegestrant·Abemaciclib

Pfizer

Phase 1/2

California, Florida, Illinois, Missouri, Texas, Washington

2023-02-23

Active, closed

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

NCT05676931Advanced Non-Small Cell Lung Cancer

DrugsQuemliclustat·Domvanalimab·Zimberelimab·Docetaxel

Gilead Sciences

Phase 2

400

Alabama, California, Florida, Illinois, Louisiana, Michigan, Virginia, Washington

2023-02-21

Recruiting

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

NCT05587712Pulmonary Arterial Hypertension

DrugSotatercept

Merck Sharp & Dohme LLC

Phase 2

California, Colorado, District of Columbia, Ohio, Pennsylvania, Tennessee, Washington, Wisconsin

2023-01-19

Active, closed

SpermQT Prospective Observational Trial

NCT05966883Male Infertility

Inherent Biosciences

Observational

1,000

California, Colorado, Connecticut, Massachusetts, Texas, Washington

2023-01-01

Active, closed

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA)

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

Michigan, Minnesota, Washington

2022-12-30

Active, closed

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

NCT05654532Breast Cancer

Accutar Biotechnology Inc

Phase 1

100

Colorado, Florida, Maryland, Tennessee, Texas, Virginia, Washington

2022-12-29

Recruiting

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

NCT05568719Hemophilia A, Hemophilia B

Pfizer

Phase 3

173

California, Florida, Indiana, Mississippi, New York, Pennsylvania, Washington

2022-12-28

Active, closed

A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer

NCT05653752Non Small Cell Lung Cancer, Breast Cancer

DrugYL202

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1

Florida, Michigan, Texas, Virginia, Washington

2022-12-20

Active, closed

Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)

NCT05696444Bladder Cancer, Prostate Cancer, Kidney Cancer, Pelvic Tumor

Medtronic - MITG

Not applicable

144

California, Illinois, New York, North Carolina, Ohio, Washington

2022-12-14

Active, closed

A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia

NCT06211634Glanzmann Thrombasthenia

Hemab ApS

Phase 1/2

California, Louisiana, Minnesota, Pennsylvania, Washington

2022-12-13

Active, closed

AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer

NCT05617755Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms

Arsenal Biosciences, Inc.

Phase 1

California, Colorado, Iowa, Michigan, New York, Texas, Washington

2022-11-29

Recruiting

Analysis of Human Movement With Assistive Devices

NCT05729061Limb Loss, Limb Weakness, Limb Paralysis, Movement Disorders

Orthocare Innovations, LLC

Not applicable

100

Washington

2022-11-28

Active, closed

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

NCT05544552Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Solid Tumor, Urothelial Carcinoma

DrugTYRA-300

Tyra Biosciences, Inc

Phase 1/2

310

Massachusetts, New York, North Carolina, Ohio, Tennessee, Washington

2022-11-22

Recruiting

Viome Nutritional Programs to Improve Clinical Outcomes for Gastrointestinal Conditions

NCT05465629Gastrointestinal Health

Viome

Not applicable

150

Washington

2022-11-18

Active, closed

BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

NCT05120271Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma, Myxoid/Round Cell Liposarcoma

Sotio Biotech Inc.

Phase 1/2

California, Texas, Washington, Wisconsin

2022-10-26

Recruiting

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

NCT05417321Advanced Solid Tumor, NSCLC

Shanghai Huaota Biopharmaceutical Co., Ltd.

Phase 1/2

Indiana, Texas, Washington

2022-08-25

Active, closed

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT05361395Extensive Stage Small Cell Lung Cancer

DrugsTarlatamab·Tecentriq·Etoposide·Atezolizumab

Amgen

Phase 1

184

California, Delaware, Michigan, New Jersey, New York, North Carolina, South Dakota, Washington

2022-08-24

Recruiting

Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c

NCT05465616Diabetes, Pre Diabetes

Viome

Not applicable

150

Washington

2022-08-22

Active, closed

Investigation to Evaluate the Safety and Effectiveness of Cochlear Implantation in Children and Adults With Unilateral Hearing Loss/Single-sided Deafness

NCT05318417Hearing Loss, Unilateral, Deafness, Unilateral

Cochlear

Not applicable

California, Colorado, Iowa, New York, North Carolina, Washington

2022-08-19

Active, closed

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT05424822Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

DrugJNJ-80948543

Janssen Research & Development, LLC

Phase 1

167

California, New York, Tennessee, Texas, Washington

2022-08-18

Active, closed

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

NCT05327530Locally Advanced or Metastatic Urothelial Carcinoma

DrugsAvelumab·Sacituzumab Govitecan

EMD Serono Research & Development Institute, Inc.

Phase 2

256

Idaho, Kansas, Maryland, Missouri, Washington, Wisconsin

2022-08-17

Active, closed

Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

NCT05222555Diffuse Large B Cell Lymphoma

DrugsTafasitamab·Lenalidomide

Incyte Corporation

Phase 1/2

New Jersey, Texas, Washington

2022-07-19

Active, closed

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

NCT05296798Locally Advanced or Metastatic Breast Cancer

DrugsGiredestrant·Phesgo·Pertuzumab·Trastuzumab

Hoffmann-La Roche

Phase 3

922

Arizona, California, Florida, Maryland, Tennessee, Texas, Washington

2022-07-18

Active, closed

Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy

NCT05506254Methylmalonic Acidemia

Alexion Pharmaceuticals, Inc.

Observational

Georgia, Pennsylvania, Tennessee, Washington

2022-07-15

Active, closed

An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia

NCT05426733Biliary Atresia

DrugOdevixibat

Albireo, an Ipsen Company

Phase 3

180

Colorado, Georgia, Indiana, Massachusetts, Missouri, New York, Ohio, Washington

2022-07-05

By invitation

Pre-hospital Ventilation Clinical Study

NCT05604430Altered Mental Status, Sepsis, Heart Failure, Hemorrhage

Zoll Medical Corporation

Observational

500

Connecticut, Louisiana, Massachusetts, Texas, Washington

2022-06-30

Recruiting

Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab

NCT05053607Multiple Myeloma, Refractory Multiple Myeloma

Pack Health

Not applicable

Texas, Washington

2022-06-17

Active, closed

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

NCT05132075Non-Small Cell Lung Cancer

DrugsOpnurasib·Docetaxel

Novartis Pharmaceuticals

Phase 3

Washington

2022-06-15

Recruiting

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

NCT05405595Advanced/Metastatic Solid Tumors

DrugsADG126·Keytruda·Pembrolizumab

Adagene Inc

Phase 1/2

186

Arizona, California, Florida, Ohio, Texas, Washington

2022-06-15

Recruiting

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

NCT05370430Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

PeproMene Bio, Inc.

Phase 1

California, Kansas, Minnesota, North Carolina, Washington

2022-06-13

Active, closed

Longitudinal Bladder Cancer Study for Tumour Recurrence

NCT05080998Urothelial Bladder Cancer

Pacific Edge Limited

Observational

450

Florida, South Carolina, Texas, Vermont, Washington

2022-06-08

Recruiting

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

NCT05365581Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma

DrugsASP2138·Ramucirumab·Fluorouracil·Leucovorin

Astellas Pharma Global Development, Inc.

Phase 1

398

California, Illinois, Kansas, New Jersey, New York, North Carolina, Texas, Washington

2022-06-07

Active, closed

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

NCT05371964Myelofibrosis

DrugsImetelstat Sodium·Ruxolitinib

Geron Corporation

Phase 1

California, Florida, New York, Washington

2022-05-04

Recruiting

Use of CereGate Therapy for Freezing of Gait in PD

NCT05292794Parkinson Disease, Freezing of Gait, Deep Brain Stimulation

CereGate Inc.

Not applicable

California, Colorado, Florida, Illinois, North Carolina, Tennessee, Washington

2022-04-18

Active, closed

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

NCT05196035Chronic Kidney Disease, Proteinuria

DrugFinerenone

Bayer

Phase 3

219

California, Florida, Maryland, Missouri, Ohio, Oregon, Utah, Washington

2022-03-28

Active, closed

Non-Guided vs. Guided Surgery to Immediately Loaded PrimeTaper Implants in Partially Edentulous Patients

NCT05264545Partially Edentulous Maxilla or Mandible

McGuire Institute

Not applicable

100

Colorado, Illinois, Nebraska, Tennessee, Texas, Washington, Wisconsin

2022-03-22

Active, closed

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

NCT05262400Breast Cancer, Solid Tumors

DrugsPF-07104091·Atirmociclib

Pfizer

Phase 1/2

235

California, Massachusetts, Michigan, Missouri, Texas, Washington

2022-03-14

Recruiting

GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

NCT04864054Hepatocellular Carcinoma, Liver Cancer, Adult, Liver Neoplasm, Metastatic Liver Cancer

Eureka Therapeutics Inc.

Phase 1/2

California, Kansas, New York, Oregon, Texas, Washington

2022-03-11

Recruiting

Inappropriate Sinus Tachycardia Registry

NCT05107635Inappropriate Sinus Tachycardia, Postural Tachycardia Syndrome

AtriCure, Inc.

Observational

500

California, Florida, Kansas, Maryland, Ohio, Texas, Utah, Washington

2022-03-01

Active, closed

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma

DrugsEvorpacept·Ramucirumab·Herceptin·Taxol

ALX Oncology Inc.

Phase 2/3

127

California, Tennessee, Virginia, Washington

2022-01-15

Active, closed

A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

NCT05071300Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

DrugEplontersen

Ionis Pharmaceuticals, Inc.

Phase 3

151

Arizona, Indiana, Maryland, Massachusetts, New York, North Carolina, Oregon, Washington

2022-01-04

Recruiting

ViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for AAA

NCT05004051Abdominal Aortic Aneurysms

ViTAA Medical Solutions

Observational

200

Alabama, Massachusetts, North Carolina, Washington

2021-12-15

Active, closed

Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

NCT05172726Plaque Psoriasis

DrugTapinarof

Organon and Co

Phase 3

Arkansas, California, Florida, Illinois, Indiana, Ohio, Oregon, Washington

2021-12-02

Active, closed

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

NCT04770779Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia

DrugMitapivat

Agios Pharmaceuticals, Inc.

Phase 3

258

Arizona, California, Massachusetts, Michigan, New York, North Carolina, Pennsylvania, Washington

2021-11-30

Recruiting

ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS)

NCT05135403Sudden Cardiac Arrest

Kestra Medical Technologies, Inc.

Observational

5,179

Washington

2021-11-20

Recruiting

Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

NCT05145127Hemophilia A, Hemophilia B

DrugMarstacimab

Pfizer

Phase 3

245

Iowa, New York, Pennsylvania, Washington

2021-11-17

Active, closed

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

NCT04980872PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)

Merck Sharp & Dohme LLC

Phase 2

Georgia, Massachusetts, Ohio, Texas, Washington

2021-11-02

Active, closed

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

NCT04931342Ovarian Cancer

DrugsCobimetinib·Ipatasertib·Giredestrant·Inavolisib

Hoffmann-La Roche

Phase 2

176

California, Missouri, North Carolina, Ohio, Oklahoma, Texas, Virginia, Washington

2021-10-07

Active, closed

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

NCT05059522Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer

DrugsCMP 001·Utomilumab·Talazoparib·Axitinib

Pfizer

Phase 3

Arkansas, California, Florida, New Jersey, New York, Pennsylvania, Texas, Washington

2021-09-29

Recruiting

A Study of NX-1607 in Adults With Advanced Malignancies

NCT05107674Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma

DrugPaclitaxel

Nurix Therapeutics, Inc.

Phase 1

345

California, Colorado, Illinois, North Carolina, Oklahoma, Texas, Virginia, Washington

2021-09-29

Active, closed

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

NCT04977024COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma

DrugCOVID-19 Vaccine

GeoVax, Inc.

Phase 2

California, Maryland, Massachusetts, New York, North Carolina, Washington

2021-09-27

Recruiting

Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction

NCT04703842Congestive Heart Failure, Heart Failure, Systolic, Heart Failure, HFrEF - Heart Failure With Reduced Ejection Fraction

Sardocor Corp.

Phase 1/2

California, Missouri, Texas, Washington

2021-09-23

Active, closed

Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa

NCT04910776Glycogen Storage Disease Type II

DrugAvalglucosidase alfa

Sanofi

Phase 3

California, Minnesota, New York, North Carolina, Ohio, Washington

2021-09-01

Active, closed

Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

NCT04541108Solid Tumor

DrugsAZD9592·Sabestomig·Volrustomig·Rilvegostomig

Presage Biosciences

Early Phase 1

Louisiana, New York, North Carolina, Ohio, Oregon, Pennsylvania, South Carolina, Washington

2021-07-26

Active, closed

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

NCT04969835Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer

Avacta Life Sciences Ltd

Phase 1

158

New York, Texas, Washington

2021-07-16

Active, closed

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

NCT04898634Prostatic Neoplasms

DrugPasritamig

Janssen Research & Development, LLC

Phase 1

216

New York, Washington

2021-07-13

Recruiting

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

NCT04669171Follicular Lymphoma, Marginal Zone Lymphoma

DrugsLenalidomide·Rituximab

Enterome

Phase 1/2

Massachusetts, Minnesota, New York, Washington

2021-07-05

Active, closed

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

NCT04895722Colorectal Cancer

DrugsPembrolizumab/Vibostolimab·MK-4830·Pembrolizumab/Favezelimab·Pembrolizumab/Quavonlimab

Merck Sharp & Dohme LLC

Phase 2

302

Florida, Georgia, Illinois, New York, Pennsylvania, Tennessee, Texas, Washington

2021-06-25

Active, closed

A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)

NCT04848779Glycogen Storage Disease Type II

DrugAlglucosidase alfa

Sanofi

Observational

New York, North Carolina, Ohio, Tennessee, Washington

2021-06-10

Active, closed

da Vinci SP® Investigational Device Exemption Study in Colorectal Procedures

NCT04403022Colorectal Cancer, Benign or Malignant Rectal or Colon Tumors

Intuitive Surgical

Not applicable

Florida, Michigan, Minnesota, Nevada, Pennsylvania, Texas, Washington

2021-06-03

Active, closed

Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection

NCT04727788Kidney Transplant Rejection

Verici Dx

Observational

550

Illinois, Maryland, Michigan, Nebraska, Ohio, Pennsylvania, Tennessee, Washington

2021-03-21

Active, closed

Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)

NCT04708041Papillomavirus Infections

DrugNonavalent HPV vaccine

Merck Sharp & Dohme LLC

Phase 3

700

California, Florida, South Carolina, Texas, Washington

2021-03-15

Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

NCT04686305Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Durvalumab

AstraZeneca

Phase 1

304

California, Kansas, Maryland, Michigan, New York, Texas, Virginia, Washington

2021-03-09

Recruiting

Single-Sided Deafness and Asymmetric Hearing Loss

NCT04506853Hearing Loss, Unilateral, Hearing Loss, Sensorineural

Med-El Corporation

Not applicable

Illinois, Iowa, New York, North Carolina, Washington

2021-02-22

Active, closed

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

NCT04431726Severe Hemophilia A

DrugEmicizumab

Hoffmann-La Roche

Phase 3

Arizona, California, Colorado, Louisiana, Michigan, Washington

2021-02-04

Active, closed

Growth Trial: Study of the Renata Minima Stent

NCT05086016Coarctation of the Aorta, Pulmonary Artery Stenosis

Renata Medical

Not applicable

California, Massachusetts, Ohio, Tennessee, Washington

2021-01-14

Active, closed

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

NCT04641442NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations

DrugArumakimig

Novartis Pharmaceuticals

Phase 2

Ohio, Pennsylvania, Texas, Washington

2020-12-18

Active, closed

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

NCT04351555Non-Small Cell Lung Cancer

DrugsTagrisso·Osimertinib·Pemetrexed·Cisplatin

AstraZeneca

Phase 3

358

California, Massachusetts, New Hampshire, New York, Texas, Virginia, Washington

2020-12-16

Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

NCT04606446Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer

DrugsPrifetrastat·Atirmociclib·Palbociclib·Letrozole

Pfizer

Phase 2

320

Arizona, California, Connecticut, Florida, Kentucky, Tennessee, Texas, Washington

2020-11-16

Active, closed

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

NCT04454658Myelofibrosis (MF)

DrugsNavitoclax·Ruxolitinib

AbbVie

Phase 1

California, New Hampshire, New York, Ohio, Oklahoma, Oregon, Texas, Washington

2020-11-11

Active, closed

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

NCT04430738Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma

DrugsTucatinib·Fluorouracil·Leucovorin·Trastuzumab

Seagen, a wholly owned subsidiary of Pfizer

Phase 2

Arizona, Colorado, District of Columbia, Missouri, New Mexico, North Carolina, Ohio, Washington

2020-09-15

Active, closed

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

NCT04370054Hemophilia A

Pfizer

Phase 3

California, Washington

2020-08-18

Active, closed

Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:

NCT02616484Pyruvate Dehydrogenase Complex Deficiency

Saol Therapeutics Inc

Phase 3

California, District of Columbia, Florida, Ohio, Pennsylvania, Texas, Utah, Washington

2020-07-14

Active, closed

Linerixibat Long-term Safety, and Tolerability Study

NCT04167358Cholestasis

GlaxoSmithKline

Phase 3

242

California, Florida, Michigan, New York, North Carolina, Pennsylvania, Texas, Washington

2020-07-14

Active, closed

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

NCT04314531Active Psoriatic Arthritis

Sun Pharmaceutical Industries Limited

Phase 3

296

California, Florida, Missouri, Nebraska, South Carolina, Texas, Washington

2020-07-01

Active, closed

Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)

NCT04184050Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission

Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1

100

Arizona, California, Kansas, New York, Oregon, Washington

2020-04-13

Active, closed

First-in-Human Study of ICT01 in Patients With Advanced Cancer

NCT04243499Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer

ImCheck Therapeutics, an Ipsen company

Phase 1/2

293

Arizona, California, Connecticut, Florida, New York, Texas, Washington

2020-03-05

Recruiting

Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

NCT04215809CLL/SLL

DrugLisaftoclax

Ascentage Pharma Group Inc.

Phase 1

144

California, Florida, Massachusetts, North Carolina, Ohio, Washington

2020-03-02

Recruiting

MDR - PMCF Study for Taperloc Complete Stems

NCT04028687Hip Arthritis, Hip Disease, Hip Fractures, Hip Injuries

Zimmer Biomet

Observational

820

Nevada, Texas, Washington

2020-02-13

Active, closed

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

NCT04191499Breast Cancer

DrugsInavolisib·Palbociclib·Fulvestrant

Hoffmann-La Roche

Phase 2/3

325

California, Massachusetts, New York, North Carolina, Tennessee, Texas, Washington

2020-01-29

Active, closed

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

NCT03997786Moderate-to-severe Chronic Plaque Psoriasis

DrugsTildrakizumab·Etanercept

Sun Pharmaceutical Industries Limited

Phase 2/3

135

California, Florida, Washington

2020-01-15

Recruiting

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

NCT04260022Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia

DrugBlinatumomab

Ascentage Pharma Group Inc.

Phase 1

242

Alabama, California, Georgia, Maryland, Ohio, Texas, Washington

2020-01-09

Active, closed

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

NCT04239625Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)

DrugALK-001

Alkeus Pharmaceuticals, Inc.

Phase 2

200

Arizona, California, Colorado, Florida, Indiana, Michigan, New York, Washington

2019-12-20

By invitation

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

NCT04138927Warm Antibody Autoimmune Hemolytic Anemia

DrugFostamatinib

Rigel Pharmaceuticals

Phase 3

California, District of Columbia, Maryland, Massachusetts, Nevada, Washington

2019-10-30

Active, closed

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

NCT04157348Eosinophilic Granulomatous Vasculitis

DrugsBenralizumab·Mepolizumab

AstraZeneca

Phase 3

140

Colorado, Michigan, Minnesota, New Mexico, New York, Pennsylvania, Texas, Washington

2019-10-29

Active, closed

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

NCT03987763Psoriasis

Bausch Health Americas, Inc.

Phase 4

California, Florida, South Carolina, Washington

2019-10-22

Active, closed

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

NCT03844048Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma

DrugsVenclexta·Venetoclax

AbbVie

Phase 3

165

Arizona, California, Illinois, Massachusetts, Michigan, New Hampshire, Washington

2019-09-06

Recruiting

Break Wave(TM) Extracorporeal Lithotripter First-in-Human Study

NCT03811171Renal Calculi, Urinary Calculi

SonoMotion

Not applicable

California, Washington

2019-08-20

Active, closed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

NCT03725007Juvenile Idiopathic Arthritis (JIA)

DrugUpadacitinib

AbbVie

Phase 1

124

Illinois, Kentucky, Massachusetts, Ohio, Oregon, Pennsylvania, Washington

2019-06-24

Recruiting

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

NCT03480971Mucositis, Nephrotoxicity, Ototoxicity

Matrix Biomed, Inc.

Phase 2

120

California, New York, North Carolina, Washington

2019-05-13

Active, closed

Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT03907527Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma

Precigen, Inc

Phase 1

Maryland, Washington

2019-04-30

Recruiting

Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer

NCT03878849Advanced Ovarian Cancer

Allarity Therapeutics

Phase 2

Oklahoma, Washington

2019-04-15

Recruiting

Clinical Pre-screening Protocol for Ovarian Cancer

NCT03877796Ovarian Cancer

Allarity Therapeutics

Observational

Florida, Georgia, New Mexico, New York, Oklahoma, Texas, Washington

2019-04-11

Recruiting

Deep Brain Stimulation (DBS) Retrospective Outcomes Study

NCT03664609Parkinson Disease, Essential Tremor, Dystonia

Boston Scientific Corporation

Observational

5,000

Arizona, California, Florida, Idaho, New York, North Carolina, Pennsylvania, Washington

2019-03-12

Active, closed

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

NCT03778229Carcinoma

DrugsSavolitinib·Osimertinib

AstraZeneca

Phase 2

367

California, District of Columbia, Maryland, Massachusetts, Minnesota, New York, Pennsylvania, Washington

2019-01-09

Active, closed

Post-Authorization Long-Term Safety Study of LUTATHERA

NCT03691064Neuroendocrine Tumors

DrugLutathera

Advanced Accelerator Applications

Observational

1,014

Arizona, Ohio, Oregon, Washington

2018-11-28

Recruiting

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

NCT03838926Relapsed or Refractory Hematologic Malignancies

DrugTrichostatin A

Vanda Pharmaceuticals

Phase 1

District of Columbia, Indiana, New Jersey, Washington

2018-09-27

Active, closed

A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

NCT03634540Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC), Kidney Cancer, Renal Cancer

DrugsBelzutifan·Cabozantinib

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

118

California, Florida, Massachusetts, Michigan, Tennessee, Texas, Washington

2018-09-27

Active, closed

Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma

NCT03600441Follicular Lymphoma

DrugAbexinostat

Xynomic Pharmaceuticals, Inc.

Phase 2

139

Illinois, Kentucky, New York, Pennsylvania, Texas, Washington

2018-08-27

Recruiting

Collection and Analyses of Physiological, Physical, and Molecular Data From a Diverse Population

NCT06381232General Health, Wellness

Viome

Observational

20,000

Washington

2018-07-23

Active, closed

A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

NCT03492177Pulmonary Arterial Hypertension

DrugSelexipag

Actelion

Phase 2

Colorado, Iowa, Washington

2018-07-23

Recruiting

A Crowd Sourcing Platform for Patients With Cancer

NCT03530826Cancer

All4Cure

Observational

5,000

Washington

2018-04-26

Active, closed

THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study

NCT02732704Aortic Regurgitation

JenaValve Technology, Inc.

Not applicable

100

California, District of Columbia, Georgia, Michigan, New York, Texas, Washington

2018-04-20

Active, closed

A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer

NCT03440450Advanced Solid Tumors, Biliary Tract Cancer

DrugFF-10832

Fujifilm Pharmaceuticals U.S.A., Inc.

Phase 1

Arizona, California, Colorado, Tennessee, Texas, Washington

2018-03-22

Active, closed

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

NCT03459846Urinary Bladder Neoplasms

DrugsOlaparib·Durvalumab

AstraZeneca

Phase 2

154

Alabama, Arizona, Florida, Kentucky, New York, Pennsylvania, Tennessee, Washington

2018-03-16

Recruiting

Mucopolysaccharidosis VII Disease Monitoring Program

NCT03604835Mucopolysaccharidosis VII, MPS VII, MPS 7, Sly Syndrome

Ultragenyx Pharmaceutical Inc

Observational

California, District of Columbia, Illinois, Michigan, New York, Utah, Washington

2018-01-29

Active, closed

A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa

NCT03019406Glycogen Storage Disease Type II-Pompe's Disease

DrugsAlglucosidase alfa·Avalglucosidase alfa

Genzyme, a Sanofi Company

Phase 2

New York, North Carolina, Washington

2017-10-12

Active, closed

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT03052608Carcinoma, Non-Small-Cell Lung

DrugsCrizotinib·Lorlatinib

Pfizer

Phase 3

296

Florida, Massachusetts, New York, Tennessee, Washington

2017-04-27

Active, closed

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

NCT03075696Non-Hodgkin's Lymphoma

DrugsGlofitamab·Tocilizumab·Obinutuzumab

Hoffmann-La Roche

Phase 1/2

940

Michigan, Missouri, New York, Pennsylvania, Washington

2017-02-21

Recruiting

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

NCT03110822Multiple Myeloma

DrugsDepo-Medrol·Solu-Medrol·Jakavi·Ruxolitinib

Oncotherapeutics

Phase 1

134

California, Florida, Maryland, Washington

2017-02-01

Active, closed

The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study

NCT02979587Congenital Heart Disease, Tetrology of Fallot, RVOT Anomaly, Pulmonary Regurgitation

Medtronic Heart Valves

Not applicable

California, Connecticut, Minnesota, Ohio, Pennsylvania, Texas, Utah, Washington

2017-01

Active, closed

Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders:

NCT03100474Essential Tremor, Parkinson's Disease, Movement Disorders, Neuropathic Pain

InSightec

Observational

500

California, Maryland, Pennsylvania, Virginia, Washington

2016-12

Active, closed

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

NCT02717624Mantle Cell Lymphoma (MCL)

DrugAcalabrutinib

Acerta Pharma BV

Phase 1

Kentucky, Michigan, New Jersey, New York, Ohio, Tennessee, Texas, Washington

2016-04-20

Active, closed

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

NCT02586857Glioblastoma Multiforme

DrugAcalabrutinib

Acerta Pharma BV

Phase 1/2

California, Massachusetts, New York, Washington

2016-01-25

Active, closed

Triathlon Tritanium Cone Augments Outcomes Study

NCT02521103Arthroplasty, Replacement, Knee

Stryker Orthopaedics

Not applicable

254

Florida, Illinois, Kentucky, Michigan, Missouri, New Jersey, Oklahoma, Washington

2015-08

Active, closed

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

NCT02213926Mantle Cell Lymphoma (MCL)

DrugAcalabrutinib

Acerta Pharma BV

Phase 2

124

Florida, Illinois, Massachusetts, New Jersey, New York, Texas, Washington

2015-03-02

Active, closed

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

NCT02180724Waldenström Macroglobulinemia (WM)

DrugAcalabrutinib

Acerta Pharma BV

Phase 2

107

California, Colorado, District of Columbia, Minnesota, New York, Tennessee, Texas, Washington

2014-09-11

By invitation

Natural Sunlight Protection and Simulated Sunlight Protection Offered by Sunscreens and Fabrics

NCT03007589Sunburn, Sun Damaged Skin, Overexposure to Sun Rays

Sun Protection Foundation

Not applicable

200

California, Hawaii, Washington

2014-04

Active, closed

Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

NCT03301168Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes

DrugsBPX-501 T cells·Rimiducid

Bellicum Pharmaceuticals

Phase 1/2

120

California, District of Columbia, Georgia, Massachusetts, New York, Oregon, Texas, Washington

2014-04

Active, closed

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

NCT02029443Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia

DrugAcalabrutinib

Acerta Pharma BV

Phase 1/2

306

Massachusetts, New York, Ohio, Texas, Utah, Washington

2014-01-30

Active, closed

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

NCT01872260Breast Cancer

DrugsAlpelisib·Ribociclib·Letrozole

Novartis Pharmaceuticals

Phase 1/2

259

California, Florida, Massachusetts, Tennessee, Texas, Washington

2013-10-22

Active, closed

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

NCT01744223Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma, Myelodysplastic Syndromes

DrugRimiducid

Bellicum Pharmaceuticals

Phase 1/2

Georgia, New York, Ohio, Oregon, Texas, Washington

2013-03

Active, closed

MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors

NCT00147056Brain Tumor

InSightec

Not applicable

Massachusetts, Washington

2012-08

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 October 2026. https://priyalifescience.com/clinical-trials-usa/state/washington

Query this register directly

GET /api/trials?country=usa&status=recruiting&format=json Try it now →

Clinical Trials in Washington, 2026

Trials with a site in Washington

About this register

How many clinical trials are recruiting in Washington?

Summary by phase

Most active sponsors

Phase	Studies	Recruiting	Share
Phase 1	78	50	21.5%
Phase 2	72	30	19.8%
Phase 1/2	60	41	16.5%
Not applicable	55	36	15.2%
Phase 3	52	21	14.3%
Observational	36	21	9.9%
Phase 2/3	5	1	1.4%
Phase 4	4	2	1.1%
Early Phase 1	1	0	0.3%